ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

27 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

12 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 1 2025 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

16 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 12 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Promotions on Executive Management Team

03 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

13 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

06 11 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 11 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

24 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

23 10 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

18 10 2024 07:20:14 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 10 2024 15:00:00 提供 Nasdaq GlobeNewswire

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

25 9 2024 00:00:00 提供 Nasdaq GlobeNewswire

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

24 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

19 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 9 2024 15:00:00 提供 Nasdaq GlobeNewswire

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

28 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

22 8 2024 07:00:00 提供 Nasdaq GlobeNewswire